We discuss the advantages and disadvantages of using international reference pricing for consistent ...
Read moreThe pricing dynamics of biosimilars, depends on the type of biosimilar, its indication and the chann...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read moreIntroduction The European landscape has seen both approvals and withdrawals of cell and gene therapi...
Read moreWe look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...
Read moreOur Market Access Analysts discuss the proposed changes to CAR-T reimbursement in the US and conside...
Read moreDigital therapeutics: a growing market The year is 2008 and Apple have just added a new category to ...
Read moreIntroduction Digital therapeutics (DTx) or digital health technologies (DHTs) are defined as product...
Read moreOur Market Access analysts summarise the EUnetHTA draft scoping process and provide considerations a...
Read moreIntroduction Market Access is critical to commercial success, so the whole organisation needs to be ...
Read more